Roche

Valuation Analysis

About the Company

Roche en bref

Roche (RO.SW) is currently trading at 358,60 CHF with a market capitalization of 247,7 Md €. The trailing P/E ratio stands at 23.42x, with a forward P/E of 16.35x. The 52-week range spans from 256,40 CHF to 383,00 CHF ; the current price is 6.4% below the yearly high. Year-over-year revenue growth stands at -1.2%. The net profit margin stands at 19.6%.

💰 Dividende

Roche pays an annual dividend of 9,80 CHF per share, representing a yield of 2.73%. The payout ratio stands at 63.93%.

📊 Avis des analystes

3 analystes évaluent Roche (RO.SW) au consensus : Acheter. L'objectif de cours moyen est de 367,00 CHF , soit un potentiel de +2.34% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 340,00 CHF à 396,00 CHF .

Roche : la thèse d'investissement en détail

Roche (RO.SW) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in Switzerland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 74.17%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 38.11% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 19.6%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

Revenue is contracting at -1.2% year-over-year — until that trend reverses, valuation is exposed to further downgrades.

À surveiller

• The forward P/E of 16.35x is meaningfully below the trailing 23.42x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Roche?

Compare top-rated brokers — low fees, trusted providers, fully regulated.